PRMT5 and breast cancer: Our speculation was supported by the enrichment of H3K4me3 marks at the PD-L1 promoter in a PRMT5-dependent manner in BC cell lines, as revealed by bioinformatics and ChIP analyses (Fig. 5D, E).